Gossamer Bio, Inc. GOSS

GOSS Company Overview

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for pulmonary hypertension and other serious diseases with significant unmet medical need. The company operates within the biotechnology and life sciences industries, with its primary strategic emphasis centered on pulmonary arterial hypertension (PAH). Gossamer Bio’s lead value driver is seralutinib, an inhaled platelet-derived growth factor receptor (PDGFR), colony stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor designed to address the underlying pathology of PAH. The company has historically pursued immunology, oncology, and pulmonary programs, though its current operational focus is concentrated on pulmonary vascular disease.

Gossamer Bio was founded in 2018 by a group of biotechnology executives associated with the “asset-centric” development model previously used at Receptos and other biotechnology ventures. The company rapidly expanded through in-licensing and acquisition of clinical-stage assets before refining its portfolio around pulmonary hypertension. Its positioning is differentiated by its inhaled therapeutic approach, intended to maximize pulmonary exposure while limiting systemic toxicity, and by its concentration on disease-modifying mechanisms rather than symptom management alone.